This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pfizer Shops Animal Health Unit

Stocks in this article: PFE JPM

NEW YORK ( TheStreet) -- Pfizer's (PFE - Get Report) shares fell slightly in premarket trading after the pharmaceutical company said Thursday it would explore the sale of its animal health and nutrition businesses.

The New York company, in a press release, said it hoped to maximize shareholder value with a full or partial separation of the two businesses, which included a sale, spinoff or other transaction.

The company said that it had asked JPMorgan (JPM - Get Report) to evaluate the business alternatives for the two units. Pfizer expected a transaction to occur for each division within the next one to two years.

"Both Animal Health and Nutrition are strong businesses," said Ian Read, Pfizer's CEO. "In exploring these alternatives, we can determine what options will best drive their future growth opportunities and expansion, and enable shareholders to potentially realize higher value for these businesses."

Pfizer's animal health unit develops vaccines and medicines for pets and livestock. It was established in 1959 and has annual sales of about $3.6 billion. The nutrition unit, which has sales of about $1.9 billion, has provided medicine for children and infants for about a century, Pfizer said on its Web site.

Pfizer shares were down 20 cents to $20.58 in premarket trading Thursday.

-- Written by Joe Deaux in New York.



>To submit a news tip, send an email to: tips@thestreet.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,422.50 +35.29 0.20%
S&P 500 2,024.92 -4.63 -0.23%
NASDAQ 4,682.33 +0.8330 0.02%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs